KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Enterprise Value: 2017-2025

Historic Enterprise Value for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to $3.0 billion.

  • Amneal Pharmaceuticals' Enterprise Value rose 17.54% to $3.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year increase of 16.38%. This contributed to the annual value of $2.4 billion for FY2024, which is 33.03% up from last year.
  • Amneal Pharmaceuticals' Enterprise Value amounted to $3.0 billion in Q3 2025, which was up 19.00% from $2.5 billion recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Enterprise Value ranged from a high of $3.0 billion in Q3 2025 and a low of $304.9 million during Q1 2023.
  • In the last 3 years, Amneal Pharmaceuticals' Enterprise Value had a median value of $2.0 billion in 2024 and averaged $1.9 billion.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Enterprise Value tumbled by 71.33% in 2023, and later spiked by 510.39% in 2024.
  • Quarterly analysis of 5 years shows Amneal Pharmaceuticals' Enterprise Value stood at $1.2 billion in 2021, then crashed by 50.29% to $603.1 million in 2022, then spiked by 200.18% to $1.8 billion in 2023, then soared by 33.03% to $2.4 billion in 2024, then climbed by 17.54% to $3.0 billion in 2025.
  • Its last three reported values are $3.0 billion in Q3 2025, $2.5 billion for Q2 2025, and $2.6 billion during Q1 2025.